IN2014CN04071A - - Google Patents
Download PDFInfo
- Publication number
- IN2014CN04071A IN2014CN04071A IN4071CHN2014A IN2014CN04071A IN 2014CN04071 A IN2014CN04071 A IN 2014CN04071A IN 4071CHN2014 A IN4071CHN2014 A IN 4071CHN2014A IN 2014CN04071 A IN2014CN04071 A IN 2014CN04071A
- Authority
- IN
- India
- Prior art keywords
- antigen
- tcdb
- relates
- tcda
- difficile
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201121149A GB201121149D0 (en) | 2011-12-08 | 2011-12-08 | Clostridium difficile toxin-based vaccine |
GBGB1217321.7A GB201217321D0 (en) | 2012-09-27 | 2012-09-27 | Vaccine |
PCT/IB2012/002955 WO2013084071A2 (en) | 2011-12-08 | 2012-12-07 | Clostridium difficile toxin-based vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014CN04071A true IN2014CN04071A (es) | 2015-10-23 |
Family
ID=47747684
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN4071CHN2014 IN2014CN04071A (es) | 2011-12-08 | 2012-12-07 |
Country Status (15)
Country | Link |
---|---|
US (1) | US9694063B2 (es) |
EP (1) | EP2788022B1 (es) |
JP (1) | JP6084631B2 (es) |
KR (1) | KR20140101835A (es) |
CN (1) | CN103974718A (es) |
AU (1) | AU2012349753A1 (es) |
BR (1) | BR112014013876A2 (es) |
CA (1) | CA2858519A1 (es) |
ES (1) | ES2704069T3 (es) |
IL (1) | IL232957A0 (es) |
IN (1) | IN2014CN04071A (es) |
MX (1) | MX2014006630A (es) |
RU (1) | RU2014127714A (es) |
SG (1) | SG11201402375VA (es) |
WO (1) | WO2013084071A2 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112013027229B1 (pt) | 2011-04-22 | 2020-10-27 | Wyeth Llc | polipeptídeo imunogênico isolado e seu uso, composição imunogênica e seu uso, célula recombinante ou progênie da mesma, e método de produção de uma toxina de clostridium difficile mutante |
BR112015004629A2 (pt) * | 2012-09-19 | 2017-11-21 | Novartis Ag | polipeptídeos de clostridium difficile como vacinas |
BR122016023101B1 (pt) * | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
WO2014197651A1 (en) * | 2013-06-05 | 2014-12-11 | Tufts University | Atoxic recombinant holotoxins of clostridium difficile as immunogens |
US10835595B2 (en) | 2014-01-06 | 2020-11-17 | The Trustees Of The University Of Pennsylvania | PD1 and PDL1 antibodies and vaccine combinations and use of same for immunotherapy |
EP3160500B1 (en) * | 2014-06-25 | 2019-08-21 | GlaxoSmithKline Biologicals S.A. | Clostridium difficile immunogenic composition |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
US10668140B2 (en) | 2017-02-24 | 2020-06-02 | University Of South Floirida | Non-toxigenic Clostridium difficile spores for use in oral vaccination |
US10555992B2 (en) | 2017-05-31 | 2020-02-11 | University Of South Florida | Immunogenic proteins against clostridium difficile |
US10933126B2 (en) | 2018-05-03 | 2021-03-02 | The Board Of Regents Of The University Of Oklahoma | Clostridium difficile immunogenic compositions and methods of use |
CA3141165A1 (en) * | 2019-05-21 | 2020-11-26 | The Regents Of The University Of California | Vaccine compositions for clostridium difficile |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5916588A (en) | 1984-04-12 | 1999-06-29 | The Liposome Company, Inc. | Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use |
US6090406A (en) | 1984-04-12 | 2000-07-18 | The Liposome Company, Inc. | Potentiation of immune responses with liposomal adjuvants |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
AU631377B2 (en) | 1988-08-25 | 1992-11-26 | Liposome Company, Inc., The | Affinity associated vaccine |
DE3841091A1 (de) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung |
DE68907045T2 (de) | 1989-01-17 | 1993-12-02 | Eniricerche Spa | Synthetische Peptide und deren Verwendung als allgemeine Träger für die Herstellung von immunogenischen Konjugaten, die für die Entwicklung von synthetischen Impfstoffen geeignet sind. |
HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
AU651949B2 (en) | 1989-07-14 | 1994-08-11 | American Cyanamid Company | Cytokine and hormone carriers for conjugate vaccines |
IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
GB2276169A (en) | 1990-07-05 | 1994-09-21 | Celltech Ltd | Antibodies specific for carcinoembryonic antigen |
DE69113564T2 (de) | 1990-08-13 | 1996-05-30 | American Cyanamid Co | Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff. |
IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
JP3755890B2 (ja) | 1992-06-25 | 2006-03-15 | スミスクライン・ビーチャム・バイオロジカルス(ソシエテ・アノニム) | アジュバント含有ワクチン組成物 |
IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
AU709586B2 (en) | 1994-10-24 | 1999-09-02 | Ophidian Pharmaceuticals, Inc. | Vaccine and antitoxin for treatment and prevention of C. difficile disease |
GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
JPH11509200A (ja) | 1995-07-07 | 1999-08-17 | オラバックス インク. | 粘膜アジュバントとしてのクロストリジウム・ディフィシール(Clostridium Difficile)トキシン |
US5707829A (en) | 1995-08-11 | 1998-01-13 | Genetics Institute, Inc. | DNA sequences and secreted proteins encoded thereby |
EP1105153A4 (en) | 1996-08-28 | 2005-01-19 | Ophidian Pharm Inc | POLYVALENT VACCINE AGAINST NEUROTOXIN (CLOSTRIDIUM BOTILINUM) |
PT1005368E (pt) | 1997-03-10 | 2009-11-19 | Coley Pharm Gmbh | Utilização de ácidos nucleicos contendo dinucleótidos cpg não metilados em combinação com alúmen como adjuvante |
GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
WO1998059053A1 (en) * | 1997-06-20 | 1998-12-30 | Queen Mary & Westfield College | Immonogenic fragments of toxin a of clostridium difficile |
DE69815692T2 (de) | 1997-09-05 | 2004-04-29 | Glaxosmithkline Biologicals S.A. | Öl in wasser emulsionen mit saponinen |
GB9725084D0 (en) | 1997-11-28 | 1998-01-28 | Medeva Europ Ltd | Vaccine compositions |
IL137809A0 (en) | 1998-02-12 | 2001-10-31 | American Cyanamid Co | Pneumococcal and meningococcal vaccines formulated with interleukin-12 |
US6303114B1 (en) | 1998-03-05 | 2001-10-16 | The Medical College Of Ohio | IL-12 enhancement of immune responses to T-independent antigens |
IL138000A0 (en) | 1998-04-09 | 2001-10-31 | Smithkline Beecham Biolog | Adjuvant compositions |
US20020009429A1 (en) * | 1999-01-29 | 2002-01-24 | Galagen, Inc. | Pharmaceutical composition comprising a selected antigen and candida species antigen and methods |
WO2000056360A2 (en) | 1999-03-19 | 2000-09-28 | Smithkline Beecham Biologicals S.A. | Vaccine against antigens from bacteriae |
US6733760B1 (en) * | 1999-04-09 | 2004-05-11 | Techlab, Inc. | Recombinant toxin A/toxin B vaccine against Clostridium difficile |
WO2000061761A2 (en) | 1999-04-09 | 2000-10-19 | Techlab, Inc. | Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines |
AU781175B2 (en) | 1999-04-09 | 2005-05-12 | Intercell Usa, Inc. | Recombinant toxin A/toxin B vaccine against Clostridium Difficile |
GB0007432D0 (en) | 2000-03-27 | 2000-05-17 | Microbiological Res Authority | Proteins for use as carriers in conjugate vaccines |
US20040049352A1 (en) * | 2000-05-10 | 2004-03-11 | Isabelle Andre | Designing modulators for glycosyltransferases |
US7939087B2 (en) | 2000-10-27 | 2011-05-10 | Novartis Vaccines And Diagnostics, Inc. | Nucleic acids and proteins from Streptococcus groups A & B |
AU2002338233A1 (en) * | 2001-03-30 | 2002-10-15 | Basf Plant Science Gmbh | Glucan chain length domains |
DE60234375D1 (de) | 2001-09-14 | 2009-12-24 | Cytos Biotechnology Ag | VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG |
AU2002347404A1 (en) | 2001-09-14 | 2003-04-01 | Cytos Biotechnology Ag | In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles |
US7226597B2 (en) | 2002-06-17 | 2007-06-05 | The Board Of Regents Of The University Of Oklahoma | Mutants of Clostridium difficile toxin B and methods of use |
US20040235139A1 (en) * | 2002-12-23 | 2004-11-25 | Demain Arnold L. | Clostridium difficile culture and toxin production methods |
RS51908B (en) | 2004-02-06 | 2012-02-29 | University Of Massachusetts | CLOSTRIDIUM DIFFICILE TOXIN ANTIBODIES AND THEIR USES |
EP1833510A4 (en) | 2004-12-27 | 2010-02-10 | Progenics Pharmaceuticals Neva | ORAL ADMINISTRATION ANTITOXIN ANTIBODIES AND METHODS OF MAKING AND USING THE SAME |
US20060228369A1 (en) | 2005-04-11 | 2006-10-12 | Program For Appropriate Technology In Health | Stabilization and preservation of temperature-sensitive vaccines |
CN101500581B (zh) | 2006-06-08 | 2013-10-30 | 科内尔研究基金会 | 编码艰难梭菌毒素a和毒素b受体结合域的密码子优化dna分子及其使用方法 |
AU2007280861B2 (en) | 2006-08-02 | 2013-02-07 | Johannes Gutenberg-Universitat Mainz | Medicament for LCT poisoning |
US8883172B2 (en) * | 2007-06-14 | 2014-11-11 | The Secretary Of State For Health | Chemically modified peptides with improved immunogenicity |
WO2008156676A1 (en) * | 2007-06-15 | 2008-12-24 | President And Fellows Of Harvard College | Methods and compositions for detecting and modulating o-glycosylation |
CA2733425A1 (en) * | 2008-08-06 | 2010-02-11 | Emergent Product Development Uk Limited | Vaccines against clostridium difficile and methods of use |
JP5740714B2 (ja) | 2009-02-20 | 2015-06-24 | ヘルス プロテクション エージェンシー | クロストリジウム・ディフィシル(Clostridiumdifficile)毒素に対する抗体 |
EP2470664A4 (en) | 2009-08-27 | 2013-01-16 | Synaptic Res Llc | NEW PROTEIN RELEASE SYSTEM FOR GENERATING INDUCED PLURIPOTENTAL STEM CELLS OR TISSUE-SPECIFIC CELLS |
US10046040B2 (en) | 2009-11-16 | 2018-08-14 | University Of Maryland, Baltimore | Multivalent live vector vaccine against Clostridium difficile-associated disease |
US20120282274A1 (en) | 2009-11-20 | 2012-11-08 | Northshore University Health System Research Institute | Targeting of the c-terminal segment of c.difficile toxin b for improved clinical diagnosis, prevention, and treatment |
CA2782406A1 (en) * | 2009-12-02 | 2011-06-09 | Tufts University | Atoxic recombinant holotoxins of clostridium difficile as immunogens |
GB0921288D0 (en) | 2009-12-04 | 2010-01-20 | Health Prot Agency | Therapies for preventing or suppressing clostridium difficile infection |
MX343356B (es) | 2010-03-30 | 2016-11-03 | Pfenex Inc * | Toxinas proteicas recombinantes de alto nivel de expresion. |
EP2558493B1 (en) * | 2010-04-15 | 2019-09-18 | Progenics Pharmaceuticals, Inc. | Antibodies for the treatment of clostridium difficile-associated infection and disease |
EP2753352B2 (en) | 2010-09-03 | 2022-08-10 | Valneva Austria GmbH | Isolated polypeptide of the toxin a and toxin b proteins of c. difficile and uses thereof |
US8431361B2 (en) | 2010-09-17 | 2013-04-30 | Board Of Regents Of The University Of Oklahoma | Bacterial cells, optimized nucleotide sequences and methods for improved expression of recombinant Clostridium difficile toxin B |
GB201016742D0 (en) * | 2010-10-05 | 2010-11-17 | Health Prot Agency | Clostridium difficile antigens |
US8906635B2 (en) | 2011-02-28 | 2014-12-09 | Northshore University Healthsystem | Methods of diagnosing Clostridium difficile infection |
BR112013027229B1 (pt) * | 2011-04-22 | 2020-10-27 | Wyeth Llc | polipeptídeo imunogênico isolado e seu uso, composição imunogênica e seu uso, célula recombinante ou progênie da mesma, e método de produção de uma toxina de clostridium difficile mutante |
SI2714911T1 (sl) | 2011-05-27 | 2017-03-31 | Glaxosmithkline Biologicals S.A. | Imunogeni sestavek |
AR087716A1 (es) * | 2011-08-31 | 2014-04-09 | Valent Biosciences Corp | Composiciones reguladoras del crecimiento de plantas, metodos de preparacion y usos de las mismas |
AR089797A1 (es) * | 2012-01-27 | 2014-09-17 | Merck Sharp & Dohme | Vacunas contra clostridum difficile que comprenden toxinas recombinantes |
GB201223342D0 (en) * | 2012-12-23 | 2013-02-06 | Glaxosmithkline Biolog Sa | Immunogenic composition |
-
2012
- 2012-12-07 ES ES12826538T patent/ES2704069T3/es active Active
- 2012-12-07 BR BR112014013876A patent/BR112014013876A2/pt not_active IP Right Cessation
- 2012-12-07 MX MX2014006630A patent/MX2014006630A/es unknown
- 2012-12-07 KR KR1020147018480A patent/KR20140101835A/ko not_active Application Discontinuation
- 2012-12-07 RU RU2014127714A patent/RU2014127714A/ru not_active Application Discontinuation
- 2012-12-07 US US14/363,387 patent/US9694063B2/en active Active
- 2012-12-07 IN IN4071CHN2014 patent/IN2014CN04071A/en unknown
- 2012-12-07 CN CN201280060487.1A patent/CN103974718A/zh active Pending
- 2012-12-07 SG SG11201402375VA patent/SG11201402375VA/en unknown
- 2012-12-07 AU AU2012349753A patent/AU2012349753A1/en not_active Abandoned
- 2012-12-07 CA CA2858519A patent/CA2858519A1/en not_active Abandoned
- 2012-12-07 JP JP2014545387A patent/JP6084631B2/ja active Active
- 2012-12-07 EP EP12826538.6A patent/EP2788022B1/en active Active
- 2012-12-07 WO PCT/IB2012/002955 patent/WO2013084071A2/en active Application Filing
-
2014
- 2014-06-05 IL IL232957A patent/IL232957A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
BR112014013876A2 (pt) | 2019-09-24 |
US20150132333A1 (en) | 2015-05-14 |
EP2788022B1 (en) | 2018-10-31 |
EP2788022A2 (en) | 2014-10-15 |
RU2014127714A (ru) | 2016-01-27 |
MX2014006630A (es) | 2014-07-09 |
CN103974718A (zh) | 2014-08-06 |
WO2013084071A3 (en) | 2013-11-07 |
US9694063B2 (en) | 2017-07-04 |
SG11201402375VA (en) | 2014-10-30 |
JP6084631B2 (ja) | 2017-02-22 |
CA2858519A1 (en) | 2013-06-13 |
IL232957A0 (en) | 2014-07-31 |
WO2013084071A2 (en) | 2013-06-13 |
AU2012349753A1 (en) | 2014-06-19 |
JP2015500827A (ja) | 2015-01-08 |
KR20140101835A (ko) | 2014-08-20 |
ES2704069T3 (es) | 2019-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014CN04071A (es) | ||
MX2013011479A (es) | Anticuerpos anti-fgfr4 y metodos de uso. | |
TN2015000050A1 (en) | Methods of treating a tauopathy | |
NZ715815A (en) | High-stability t-cell receptor and preparation method and application thereof | |
PH12014501427B1 (en) | Anti-phf-tau antibodies and their uses | |
CR20150046A (es) | Anticuerpos anti-cd79b e inmunoconjugados | |
MX2013015311A (es) | Polipeptidos de enlace de pcsk9 y metodos de uso. | |
MX2014002053A (es) | Anticuerpos anti -mcsp y metodos de uso. | |
IN2014DN05885A (es) | ||
MX2019015604A (es) | Anticuerpos anti-tau y usos de los mismos en el tratamiento de una tauopatia. | |
MX340555B (es) | Anticuerpos contra il-18r1 y usos de los mismos. | |
TN2013000378A1 (en) | Anti - sclerostin antibody crystals and formulations thereof | |
AU337887S (en) | Allsaw | |
MX2012011829A (es) | Anticuerpos de anti-poliubiquitina y metodos de uso. | |
AU2013225816A8 (en) | Compositions and methods for treating Type III Gaucher Disease | |
PH12015501854A1 (en) | Factor ix polypeptide formulations | |
EP4023243A3 (en) | Compositions and methods for treating celiac sprue disease | |
WO2013123046A3 (en) | Cathode buffer materials and related devices and methods | |
MX357675B (es) | Anticuerpos anti-jagged y métodos de uso. | |
UA112760C2 (uk) | Теобромін у комбінації з гвайфенезином для лікування кашлю | |
MX2023003000A (es) | Formulaciones de liberacion modificada de viloxacina. | |
IN2015DN00820A (es) | ||
AU337888S (en) | Allsaw | |
MX2016009665A (es) | Composiciones y metodos para el tratamiento de la hemorragia cerebral. | |
NZ629420A (en) | Sheep nematode vaccine |